Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.
But a new drug made by Seattle-based Gilead Sciences Inc. appears to offer hope for fighting the disease, according to a study published online today in the New England Journal of Medicine in advance of its March 13 print issue.
The phase 2 study involved 125 patients aged 33 to 87 with indolent non-Hodgkin lymphoma (iNHL) who had not responded to conventional treatments or had relapsed within six months of therapy. The patients, who were from the Seattle area, around the United States and Europe, were given a twice-daily dose of idelalisib, a highly selective oral drug that inhibits phosphoinositide 3-kinase (PI3K) delta. P13K deltas are a family of enzymes seen in many types of B-cell malignancies.
Following treatment with idelalisib, tumor size shrunk by at least half in 57 percent of the patients and 6 percent had no measurable evidence of cancer.
"These are patients who had exhausted current standard therapies," said Ajay Gopal, M.D., a member of Fred Hutchinson Cancer Research Center's Clinical Research Division and the study's lead and corresponding author. "In terms of effective therapy available, there really wasn't much left."
Indolent non-Hodgkin lymphomas comprise about one-third of all cases of NHL. About 20,000 people in the United States were diagnosed with iNHL in 2012 and approximately 7,000 died of the disease. The standard treatment for iNHL is a combination of rituximab, a drug that targets the protein CD20 found on B cells, and chemotherapy.
While conventional treatment can be initially effective, iNHLs relapse over time and can lead to life-threatening complications such as infections and marrow failure. And unlike the toxic effects of chemotherapy, the most common side effects among patients in the trial were diarrhea and colitis, which occurred in a minority of participants and could usually be managed with dosage adjustments.
The NEJM paper, which was funded by Gilead Sciences and involved co-authors from 17 institutions in the U.S. and Europe, is the first publication of clinical data on idelalisib. The U.S. Food and Drug Administration (FDA) accepted the drug for review in early January and also gave it a Breakthrough Therapy designation for treatment of relapsed chronic lymphocytic leukemia (CLL) based on the results of another clinical trial.
Gopal, who helped write the protocol for the trial and treated many of the patients involved, said while it doesn't appear that the drug is curative, it holds tremendous promise for helping to control the disease for long periods of time.
"I think there's going to be a lot of interest in it," he said.
Gopal, also an associate professor at the University of Washington School of Medicine and the director of clinical research for hematology at Seattle Cancer Care Alliance, said depending on the FDA review, idelalisib could be approved for clinical use later this year. Such drugs, he said, represent a highly targeted and less harmful approach to treating cancer.
"Chemotherapy is a very blunt instrument," he said. "This is much more specific."
Deborah Bach | EurekAlert!
Real-time imaging of lung lesions during surgery helps localize tumors and improve precision
30.07.2015 | American Association for Thoracic Surgery
Experimental MERS vaccine shows promise in animal studies
29.07.2015 | NIH/National Institute of Allergy and Infectious Diseases
Glacier decline in the first decade of the 21st century has reached a historical record, since the onset of direct observations. Glacier melt is a global phenomenon and will continue even without further climate change. This is shown in the latest study by the World Glacier Monitoring Service under the lead of the University of Zurich, Switzerland.
The World Glacier Monitoring Service, domiciled at the University of Zurich, has compiled worldwide data on glacier changes for more than 120 years. Together...
Using ultracold atoms trapped in light crystals, scientists from the MPQ, LMU, and the Weizmann Institute observe a novel state of matter that never thermalizes.
What happens if one mixes cold and hot water? After some initial dynamics, one is left with lukewarm water—the system has thermalized to a new thermal...
Physicists from Regensburg and Marburg, Germany have succeeded in taking a slow-motion movie of speeding electrons in a solid driven by a strong light wave. In the process, they have unraveled a novel quantum phenomenon, which will be reported in the forthcoming edition of Nature.
The advent of ever faster electronics featuring clock rates up to the multiple-gigahertz range has revolutionized our day-to-day life. Researchers and...
Researchers have developed an ultrafast light-emitting device that can flip on and off 90 billion times a second and could form the basis of optical computing.
Joint BioEnergy Institute study identifies bacterial protein that is key to protecting rice against bacterial blight
A bacterial signal that when recognized by rice plants enables the plants to resist a devastating blight disease has been identified by a multi-national team...
23.07.2015 | Event News
10.07.2015 | Event News
25.06.2015 | Event News
03.08.2015 | Materials Sciences
03.08.2015 | Life Sciences
03.08.2015 | Life Sciences